152 related articles for article (PubMed ID: 24289614)
1. Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.
Wang SY; Zhu WH; Vargulick S; Lin SB; Meng ZQ
Asian Pac J Cancer Prev; 2013; 14(10):5995-6000. PubMed ID: 24289614
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization.
He JJ; Yin XX; Wang T; Chen MY; Li XL; Yang XJ; Shao HY
J Cancer Res Ther; 2021 Jul; 17(3):777-783. PubMed ID: 34269313
[TBL] [Abstract][Full Text] [Related]
3. Incidence, risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma: a prospective cohort study.
Hao JF; Zhang LW; Bai JX; Li YJ; Liu JN; Zhang XL; Han JM; Li X; Jiang H; Cao N
Indian J Cancer; 2015 Feb; 51 Suppl 2():e3-8. PubMed ID: 25712839
[TBL] [Abstract][Full Text] [Related]
4. Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.
Li CP; Chao Y; Chen LT; Lee RC; Lee WP; Yuan JN; Yen SH; Lee SD
Scand J Gastroenterol; 2008 Aug; 43(8):992-9. PubMed ID: 19086281
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment.
Lima M; Dutra S; Gomes FV; Bilhim T; Coimbra É
Acta Med Port; 2018 Jan; 31(1):22-29. PubMed ID: 29573765
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.
Aoe M; Kanemitsu T; Ohki T; Kishi S; Ogura Y; Takenaka Y; Hashiba T; Ambe H; Furukawa E; Kurata Y; Ichikawa M; Ohara K; Honda T; Furuse S; Saito K; Toda N; Mise N
Clin Exp Nephrol; 2019 Sep; 23(9):1141-1146. PubMed ID: 31183589
[TBL] [Abstract][Full Text] [Related]
7. Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride.
Sohara N; Takagi H; Abe T; Hashimoto Y; Kojima A; Takahashi H; Nagamine T; Mori M
Support Care Cancer; 1999 Mar; 7(2):84-8. PubMed ID: 10089088
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study.
Yang H; Seon J; Sung PS; Oh JS; Lee HL; Jang B; Chun HJ; Jang JW; Bae SH; Choi JY; Yoon SK
J Vasc Interv Radiol; 2017 Nov; 28(11):1503-1511.e2. PubMed ID: 28941589
[TBL] [Abstract][Full Text] [Related]
9. Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma.
Rose DM; Chapman WC; Brockenbrough AT; Wright JK; Rose AT; Meranze S; Mazer M; Blair T; Blanke CD; Debelak JP; Pinson CW
Am J Surg; 1999 May; 177(5):405-10. PubMed ID: 10365881
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study.
Huo TI; Wu JC; Lee PC; Chang FY; Lee SD
Liver Int; 2004 Jun; 24(3):210-5. PubMed ID: 15189271
[TBL] [Abstract][Full Text] [Related]
11. Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis.
Lu H; Zheng C; Liang B; Xiong B
BMC Cancer; 2021 May; 21(1):513. PubMed ID: 33962555
[TBL] [Abstract][Full Text] [Related]
12. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin.
Sakamoto T; Saito Y; Kobayashi M; Yamada T; Takekuma Y; Nakai M; Ogawa K; Iseki K; Sugawara M
Support Care Cancer; 2020 Jul; 28(7):3251-3257. PubMed ID: 31732854
[TBL] [Abstract][Full Text] [Related]
13. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Nagai K; Nakagawa T; Sugawara T; Hanaoka H; Kanai F; Yokosuka O
Hepatology; 2018 Feb; 67(2):575-585. PubMed ID: 28746788
[TBL] [Abstract][Full Text] [Related]
14. [Impact of preventive administration of antiemetic drugs on risk of acute nausea and vomiting induced by transcatheter arterial chemoembolization in patients with hepatocellular carcinomas - a retrospective study].
Kabuki M; Higashihara H; Kakuda M; Fujita Y; Masuda J; Kin K; Ueguchi T; Osuga K; Tomiyama N
Gan To Kagaku Ryoho; 2013 Feb; 40(2):197-201. PubMed ID: 23411955
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization.
Cho HS; Seo JW; Kang Y; Bae EJ; Kim HJ; Chang SH; Park DJ
Clin Exp Nephrol; 2011 Oct; 15(5):714-719. PubMed ID: 21695415
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis.
Siriwardana RC; Niriella MA; Dassanayake AS; Liyanage CA; Upasena A; Sirigampala C; de Silva HJ
BMC Gastroenterol; 2015 Aug; 15():96. PubMed ID: 26239844
[TBL] [Abstract][Full Text] [Related]
17. [Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].
Jeon SH; Park KS; Kim YH; Shin YS; Kang MK; Jang BK; Chung WJ; Cho KB; Hwang JS
Korean J Gastroenterol; 2007 Sep; 50(3):176-82. PubMed ID: 17885283
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
[TBL] [Abstract][Full Text] [Related]
19. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
[TBL] [Abstract][Full Text] [Related]
20. [Incidence and risk factors of acute renal failure after transcatheter arterial chemoembolization for hepatocellular carcinoma].
Jang BK; Lee SH; Chung WJ; Park KS; Cho KB; Hwang JS; Kim YH; Choi JS; Kwon JH
Korean J Hepatol; 2008 Jun; 14(2):168-77. PubMed ID: 18617764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
